Phase 1 Trial of Siplizumab and Dose-Adjusted EPOCH-Rituximab in T- and NK-Cell Lymphomas

Clinical trial NCT01445535 · COMPLETED

Trial details

NCT number: NCT01445535
Sponsor: National Cancer Institute (NCI)
Status: COMPLETED
Phase: Phase 1
Study type: INTERVENTIONAL

T-Cell Peripheral Lymphoma Gamma Delta Hepatosplenic T-Cell Lymphoma Subcutaneous Panniculitis-Like T-Cell Lymphoma NK T-Cell Lymphoma

Start date: 2009-01-13
Primary completion: 2011-04-01
Enrollment: 15

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.